Dr. Xin Fan is a researcher at the Department of Nuclear Medicine, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School. He earned his Ph.D. in Medicine through a joint program between Tongji University and the National University of Singapore, specializing in nuclear medicine and molecular imaging.

His research focuses on PET/CT radiomics, artificial intelligence, and multi-omics integration for cancer diagnosis and prognosis, particularly in head and neck tumors, thyroid cancer, and neuroendocrine tumors. He is also active in peptide receptor radionuclide therapy (PRRT), alpha-emitter targeted therapy, and studying molecular mechanisms of tumor metastasis and treatment response.

He has published in leading journals such as Theranostics, European Journal of Nuclear Medicine and Molecular Imaging, The Oncologist, Small, and Digital Health, contributing significantly to precision oncology through quantitative molecular imaging and personalized radionuclide therapy.

Dr.Mafalda Ingenito is a resident doctor in General Surgery at the University of Naples “Federico II.” Her clinical focus includes breast surgery, endocrine and abdominal wall procedures, and multidisciplinary management of breast carcinoma. She is actively involved in oncoplastic and reconstructive breast surgery, with experience in diagnostic imaging (ultrasound, mammography, MRI) and preoperative planning.

 Dr.Theodoros Karantanos is an Assistant Professor of Oncology at the Johns Hopkins University School of Medicine and an attending physician in Leukemia and Bone Marrow Transplantation. He specializes in acute myeloid and lymphoblastic leukemia and chronic myeloid neoplasms, including MDS, MPN, and overlap syndromes. He has extensive research experience in immune regulation, genomic mechanisms of disease progression, and development of novel targeted therapies. He has received numerous prestigious awards, including NIH/NHLBI K08, and actively contributes as a principal investigator on multiple funded research projects.

Dr. Byung Chull An obtained his Ph.D. in Biomaterials Engineering from Korea University in 2010. He began his research career as a Researcher at the Korea Atomic Energy Research Institute (KAERI) and subsequently worked as a Postdoctoral Fellow at the UMass Medical School (USA) under Dr. Mitsuo Ikebe. He later joined the Korea Research Institute of Bioscience and Biotechnology and served as an Assistant Professor at Chonnam National University Medical School before assuming his current position as Senior Researcher at Cell Biotech Co., Ltd. His pioneering work focuses on genetically engineered probiotics as drug delivery systems for cancer therapy, particularly colorectal cancer (CRC). Dr. An discovered the Lactobacillus rhamnosus-derived therapeutic protein P8, which suppresses CRC proliferation and restores gut microbiota diversity. His research demonstrates that probiotic-based drug delivery offers multiple advantages — safety, oral delivery, persistence, and cost-effectiveness — in comparison to conventional chemotherapy. He has authored over 44 peer-reviewed SCI papers, filed 18 Korean patents, 1 U.S. patent, and registered 8 genes in GenBank.

Dr. Yongqiang Zhou is a cancer biologist and biomedical researcher affiliated with Lanzhou University, China. His work focuses on molecular and cellular mechanisms driving liver diseases, particularly hepatocellular carcinoma, fibrosis, and immune microenvironment modulation. He has authored multiple high-impact publications in journals such as Molecular Cancer, Cell Death and Disease, and The American Journal of Pathology. His research integrates molecular genetics, immunology, and systems biology to explore new therapeutic targets in liver regeneration and cancer progression.

Dr. Tushar Pandey MBBS, MD, DM (Clinical Hematology) a Clinical Hematologist, Hemato-Oncologist, and Bone Marrow Transplant (BMT) & CAR-T Cell Therapy Physician, serving as Director & Head of the Raghav Institute of Hematology, Hemato-Oncology & BMT (R.I.H.O.B) under Raghav Healthcare, Haldwani, Uttarakhand. The region’s first dedicated Hematology Institute. He is the first DM-certified Clinical Hematologist from Kumaon and adjoining areas of Uttar Pradesh, with specialized training from PGIMER Chandigarh, IMS & SUM Hospital Bhubaneswar, Johns Hopkins University (USA), Imperial College London, and EBMT Europe. Dr. Pandey has successfully performed over 50 stem cell transplants and multiple CAR-T therapies, with expertise spanning benign and malignant hematological disorders including leukemia, lymphoma, myeloma, thalassemia, hemophilia, and ITP. He also serves as Program Director of Hemato-Oncology at the International Association for Integrated Oncology (IAIO) and has authored over 15 publications in reputed national and international journals

• I am Dr. Kunal Goyal, a Hematologist with a deep passion for advancing the treatment of blood cancers. I specialize in Bone Marrow Transplantation (BMT) and cutting-edge Cellular Therapies, particularly Chimeric Antigen Receptor T-cell (CAR-T) therapies.
• My journey in hematology began with a strong academic foundation. I earned my MBBS with Gold Medal honors, followed by an MD (Silver Medallist) and a DM in Clinical Hematology. I had the privilege of training at Tata Memorial Centre (ACTREC), Mumbai, where I honed my skills in BMT and CAR-T therapies as a Specialist senior Resident.
• I am dedicated to providing the highest quality care to my patients.
• I am proud to have played a key role in establishing and leading the Bone Marrow Transplant and CAR-T Therapy program at Kokilaben Dhirubhai Ambani Hospital, Navi Mumbai and BMT unit at HBCH (TATA- Varanasi in 2022)
• I also run a leading cancer day care chain ICTC Mumbai (Mumbai based) to maintaining highest standard of treatment while keeping treatment affordable for the needy patients.
• I am an active member of leading professional organizations such as ISHBT, ISBMT, ASCO, and ASH (trainee), staying abreast of the latest advancements in the field.
• I believe in a patient-centered approach to care, emphasizing personalized treatment plans and providing comprehensive support throughout the treatment journey.